CANOPY GROWTH CORP (CGC)
CA1380357048 - Common Stock
Overall CGC gets a fundamental rating of 2 out of 10. We evaluated CGC against 194 industry peers in the Pharmaceuticals industry. CGC may be in some trouble as it scores bad on both profitability and health. CGC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CGC has reported negative net income.
In the past year CGC has reported a negative cash flow from operations.
In the past 5 years CGC always reported negative net income.
In the past 5 years CGC always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -45.81%, CGC perfoms like the industry average, outperforming 40.10% of the companies in the same industry.
CGC's Return On Equity of -110.77% is on the low side compared to the rest of the industry. CGC is outperformed by 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.81% | ||
| ROE | -110.77% | ||
| ROIC | N/A |
ROA(3y)-63.49%
ROA(5y)-47.06%
ROE(3y)-181.56%
ROE(5y)-123.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CGC has a Gross Margin (31.47%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CGC has grown nicely.
The Profit Margin and Operating Margin are not available for CGC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.93%
GM growth 5Y16.63%
2. Health
2.1 Basic Checks
CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGC has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CGC has been reduced compared to 5 years ago.
Compared to 1 year ago, CGC has an improved debt to assets ratio.
2.2 Solvency
CGC has an Altman-Z score of -9.24. This is a bad value and indicates that CGC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CGC (-9.24) is worse than 73.44% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that CGC is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.85, CGC is doing worse than 71.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.24 |
ROIC/WACCN/A
WACC10.15%
2.3 Liquidity
CGC has a Current Ratio of 1.39. This is a normal value and indicates that CGC is financially healthy and should not expect problems in meeting its short term obligations.
CGC's Current ratio of 1.39 is on the low side compared to the rest of the industry. CGC is outperformed by 77.08% of its industry peers.
CGC has a Quick Ratio of 1.07. This is a normal value and indicates that CGC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CGC (1.07) is worse than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 63.30% over the past year.
CGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.56%.
CGC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.58%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y-18.39%
Revenue growth 5Y5.6%
Sales Q2Q%-23.25%
3.2 Future
CGC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.90% yearly.
Based on estimates for the next years, CGC will show a quite strong growth in Revenue. The Revenue will grow by 11.27% on average per year.
EPS Next Y60.39%
EPS Next 2Y36.48%
EPS Next 3Y19.58%
EPS Next 5Y14.9%
Revenue Next Year-19.48%
Revenue Next 2Y-6.45%
Revenue Next 3Y-0.18%
Revenue Next 5Y11.27%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CGC's earnings are expected to grow with 19.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.48%
EPS Next 3Y19.58%
5. Dividend
5.1 Amount
No dividends for CGC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CANOPY GROWTH CORP
NASDAQ:CGC (12/4/2024, 8:00:00 PM)
After market: 3.64 +0.03 (+0.83%)3.61
+0.1 (+2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap366.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.81% | ||
| ROE | -110.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.47% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y60.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y-18.39%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y